Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis

Published:2022-05-26 Issue:1 Volume:40 Page:86-97
ISSN:0888-0018
Container-title:Pediatric Hematology and Oncology
language:en
Short-container-title:Pediatric Hematology and Oncology

Author:

Mohapatra Debabrata¹^ORCID,Gupta Aditya Kumar¹^ORCID,Haldar Partha²^ORCID,Meena Jagdish Prasad¹^ORCID,Tanwar Pranay³,Seth Rachna¹

Affiliation:

1. Division of Pediatric Oncology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

2. Department of Community Medicine, All India Institute of Medical Sciences, New Delhi, India

3. Laboratory Oncology Unit, Dr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Publisher

Informa UK Limited

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/08880018.2022.2072986

Reference38 articles.

1. Reactivations in Multisystem Langerhans Cell Histiocytosis: Data of the International LCH Registry

2. Reactivation and risk of sequelae in Langerhans cell histiocytosis

3. Salvage treatment of relapsed/refractory LCH

4. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study

5. Recurrent BRAF mutations in Langerhans cell histiocytosis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature;Cancer Reports;2024-08

2. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial;JCO Precision Oncology;2024-06

3. Advances in our understanding of genetic markers and targeted therapies for pediatric LCH;Expert Review of Hematology;2024-05-11

4. Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study;Journal of Cancer Research and Clinical Oncology;2024-01

5. Central nervous system disorders secondary to histiocytoses: neurodegeneration with potential for improvement;Rinsho Shinkeigaku;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3